Darunavir
Darunavir is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Darunavir; Generic name: DARUNAVIR; Drug class: Protease Inhibitor [EPC].
| Brand name | Darunavir |
|---|---|
| Generic name | DARUNAVIR |
| Drug class | Protease Inhibitor [EPC] |
| Manufacturer | Viona Pharmaceuticals Inc |
| Used for | 1 INDICATIONS AND USAGE Darunavir, co-administered with ritonavir (darunavir/ritonavir), in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV-1) infection in adult and pediatric patients 3 years of age and older [see Use in Specific Populations ( 8.4 ) and Clinical Studies ( 14 )]. Darunavir is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older. Darunavir must be co-administered with ritonavir (darunavir/ritonavir) and with other antiretroviral agents. ( 1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION Testing: In treatment-experienced patients, treatment history genotypic and/or phenotypic testing is recommended prior to initiation of therapy with darunavir/ritonavir to assess drug susceptibility of the HIV-1 virus ( 2.1 , 12.4 ) Monitor serum liver chemistry tests before and during therapy with darunavir/ritonavir. ( 2.1 , 2.2 , 5.2 ) Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 |
| Active ingredient(s) | DARUNAVIR |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04a542b3-15ad-4a8a-aab4-ace8e08732f3 |